The A.P.P.A.® PROJECT: formulation, stability and quality study of a pediatric galenic preparation for the treatment of sickle cell disease at Saint Damien Hospital in Haiti.

Abstract

In Haiti sickle cell disease is a widespread disorder and it is associated with a high mortality. Because of this, in 2016, N.P.H. St Damien Hospital in Port-au-Prince required a medicine based on hydroxyurea to treat pediatric patients. Since there is no specific formulation on the market, in the context of the A.P.P.A.^® Project at the University of Turin, a galenic formulation was studied along with a method to assess its quality and its stability over time. The medicine was introduced on site following the training of local staff and it is now dispensed to nearly 50 patients.